Supernus Pharmaceuticals exec sells $129,676 in stock
Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), recently executed a series of stock transactions ...
FDA approves Qelbree label update for ADHD treatment
ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...
manilatimes3d
Benitec Biopharma to Participate in Upcoming Conferences in January and February
Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec” or the "Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence ...
Supernus announces U.S. FDA approved an update for label for Qelbree
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to ...
Monthly Prescribing Reference3d
Labeling for ADHD Med Qelbree Updated With Lactation, Pharmacodynamic Data
The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...
Taiwan News1mon
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada
MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission ...
Business Insider1mon
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada
Qelbree ® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Knight entered into an agreement in December 2023 with Supernus Pharmaceuticals ...